Nuvation Bio
NUVB
Nuvation Bio (NUVB) news
Recent news
Nuvation Bio's Phase 3 Sigma study enrollment underway
AInvest Wire · Aug 20, 2026Nuvation Bio gets FDA fast track designation
AInvest Wire · Aug 20, 2026Nuvation Bio gets FDA fast track designation
AInvest Wire · Aug 20, 2026Nuvation Bio shares down 1.3% after Q2 results
AInvest Wire · Aug 6, 2026Nuvation Bio shares down 2.4% premarket after Q2 results
Nuvation Bio Inc. (NYSE: NUVB) reported second-quarter 2026 financial results on August 6, 2026, with shares declining 2.4% in premarket trading following the release. The company reported a net loss of $62.8 million, or $(0.18) per share, for the quarter, compared to a net loss of $59.0 million ,…
AInvest Wire · Aug 6, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.